Clinical Trials Logo

Pituitary Diseases clinical trials

View clinical trials related to Pituitary Diseases.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06053437 Completed - Pituitary Adenoma Clinical Trials

Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.

Hyp'Op
Start date: February 1, 2023
Phase:
Study type: Observational

Predicting the outcome of pituitary surgery, particularly the risk of complications, is a critical determinant in selecting the appropriate treatment modality for patients. To date, only a limited number of risk factors have been identified for complications following pituitary surgery, including tumor size, younger age, and previous surgical intervention. Furthermore, existing studies have demonstrated that prolactin levels can serve as a surrogate marker for assessing pituitary function, specifically revealing associations between elevated prolactin levels and anterior pituitary insufficiencies. In a retrospective study on the "HYP'OP" cohort, the aim of the study is to identify predictive factors for both surgical outcomes and complications.

NCT ID: NCT05782725 Completed - Clinical trials for Polycystic Ovary Syndrome

Subclinical Hypothyroidism and Normogonadotropic Anovulation

Start date: March 1, 2023
Phase:
Study type: Observational

Thyroid hormones (TH) can modify the functioning of the hypothalamic-pituitary-ovarian axis, affecting the functions of granulosa cells and the development and apoptosis of preantral follicles. TH receptors are present within the oocytes, and TH and anti-thyroid antibodies (ATA) are present in the follicular fluid. Improper thyroid function can cause ovulation disorders, luteal phase failure, impaired endometrial receptivity and result in implantation failures and recurrent miscarriages. While overt hypothyroidism is treated to improve fertility, the effect of subclinical hypothyroidism (SCH) and the presence of circulating ATAs on fertility and obstetric outcomes is uncertain and data on ovarian reserve rates are conflicting. Among the causes of ovulation disorders (group II according to the WHO classification), polycystic ovary syndrome (PCOS) dominates, found in 3-15% of women of reproductive age, and the remaining group of causes is the so-called Hypothalamic-Pituitary-Ovarian Axis Dysfunction (HPOD). The exact etiology of both entities is unknown.

NCT ID: NCT05772832 Completed - Postoperative Pain Clinical Trials

COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

Start date: November 17, 2021
Phase:
Study type: Observational [Patient Registry]

In patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist "Dexmedetomidine" and the rapid and short-acting opioid "Remifentanil" using the "Numerical Rating Scale" (NRS) administered alongside propofol in perioperative maintenance anesthesia. .

NCT ID: NCT05088252 Completed - Pituitary Neoplasms Clinical Trials

Desflurane and Anesthesia Recovery Period in Endonasal Endoscopic Pituitary Adenoma Resection

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Nasal packing is required after endoscopic pituitary adenoma resection. The patient can only breathe through the mouth. The blood and secretion in the nasal cavity may be inhaled into the trachea after the operation. GH-secreting pituitary adenoma causes pharyngeal soft tissue and tongue hypertrophy. These conditions increase the risk of respiratory obstruction and hypoxemia during anesthesia recovery. Propofol total intravenous anesthesia has a rapid effect and a low incidence of nausea and vomiting. Patients anesthetized with desflurane recover quickly is conducive to early recovery of respiratory function and orientation. This study intends to compare the effects of desflurane and propofol on the quality of anesthesia recovery period in patients undergoing endonasal endoscopic pituitary adenoma resection and to provide clinical evidence for the use of desflurane in neurosurgical anesthesia.

NCT ID: NCT05070091 Completed - COVID-19 Clinical Trials

The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.

ENDO-COVID19
Start date: January 26, 2021
Phase:
Study type: Observational

The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.

NCT ID: NCT04902235 Completed - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)

Start date: July 6, 2021
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, corticorelin hormone (CRH) has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of CRH in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following CRH in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04865744 Completed - Healthy Clinical Trials

The Effect of Semaglutide on Pituitary Function

Start date: May 19, 2021
Phase: Phase 4
Study type: Interventional

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

NCT ID: NCT04840771 Completed - Pituitary Adenoma Clinical Trials

Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery

Start date: June 1, 2020
Phase:
Study type: Observational

This study evaluates the structural parameters, by spectral domain optical coherence tomography (OCT), retinal vessel density, using OCT angiography, and visual acuity in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

NCT ID: NCT04782596 Completed - Pituitary Adenoma Clinical Trials

Transnasal Endoscopic Pituitary Surgery - the Effect of Posterior Nasal Septum Resection on Nasal Functions

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The aim of the project is to compare the effect of different extent of resection of the posterior part of the septum on the postoperative nasal functions.

NCT ID: NCT04546386 Completed - Pituitary Adenoma Clinical Trials

Long-term Follow up for Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery.

Start date: January 10, 2019
Phase:
Study type: Observational

This study investigates the retinal vascular features, using optical coherence tomography angiography, in patients during one year's follow up after the endoscopic endonasal surgery to remove an intra-suprasellar pituitary adenoma compressing the optic nerve.